Known targets — ChEMBL curated mechanism
APH1AAPH1BNCSTNPSEN1PSEN2PSENEN
The experimentally established mechanism targets of Nirogacestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 known ✓ | P49768 | 20/20 | 1.00 |
| ▸ | PSEN2 known ✓ | P49810 | 20/20 | 1.00 |
| ▸ | APH1B known ✓ | Q8WW43 | 20/20 | 1.00 |
| ▸ | NCSTN known ✓ | Q92542 | 20/20 | 1.00 |
| ▸ | APH1A known ✓ | Q96BI3 | 20/20 | 1.00 |
| ▸ | PSENEN known ✓ | Q9NZ42 | 20/20 | 1.00 |
| ▸ | GSAP | A4D1B5 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nirogacestat SCHEMBL21050500 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL26374369 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL13184912 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL19422226 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL29658278 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL13184754 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL1796299 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL29388600 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL31142147 | 0.99 | PSEN1 (0.99) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Nirogacestat SCHEMBL30074517 | 0.99 | PSEN1 (0.99) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312480-A1 | SYNTHESIS OF NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312480-A1 | SYNTHESIS OF NIROGACESTAT | SPRINGWORKS THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312480-A1 | SYNTHESIS OF NIROGACESTAT | FNTA, NMT2, PNMT | PSEN1 2505/4885PSEN2 1089/4885APH1B 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.